C
Curtis Cooper
Researcher at Ottawa Hospital
Publications - 47
Citations - 1780
Curtis Cooper is an academic researcher from Ottawa Hospital. The author has contributed to research in topics: Hepatitis C & Hepatitis C virus. The author has an hindex of 19, co-authored 47 publications receiving 1566 citations. Previous affiliations of Curtis Cooper include Ottawa Hospital Research Institute & University of Ottawa.
Papers
More filters
Journal ArticleDOI
Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection
Marc Bourlière,Stuart C. Gordon,Steven L. Flamm,Curtis Cooper,Alnoor Ramji,Myron J. Tong,Natarajan Ravendhran,John M. Vierling,Tram T. Tran,S. Pianko,Meena B. Bansal,Victor de Ledinghen,Robert H. Hyland,Luisa M. Stamm,Hadas Dvory-Sobol,Evguenia S. Svarovskaia,Jie Zhang,K.C. Huang,G. Mani Subramanian,Diana M. Brainard,John G. McHutchison,Elizabeth C. Verna,Peter Buggisch,Charles S. Landis,Ziad Younes,Michael P. Curry,Simone I. Strasser,Eugene R. Schiff,K. Rajender Reddy,Michael P. Manns,Kris V. Kowdley,Stefan Zeuzem +31 more
TL;DR: Sofosbuvir‐velpatasvir‐voxilaprevir taken for 12 weeks provided high rates of sustained virologic response among patients across HCV genotypes in whom treatment with a DAA regimen had previously failed.
Journal ArticleDOI
A Review of Low-Dose Ritonavir in Protease Inhibitor Combination Therapy
TL;DR: Evidence suggests that increased exposure to protease inhibitors is clinically relevant and additional study will elucidate the advantages and disadvantages of twice-daily, low-dose ritonavir-boosted regimens and determine whether once-daily regimens based on this principle will have a lasting role in clinical practice.
Journal ArticleDOI
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C
Mark S. Sulkowski,Curtis Cooper,Béla Hunyady,Jidong Jia,Pavel Ogurtsov,Markus Peck-Radosavljevic,Mitchell L. Shiffman,Cihan Yurdaydin,Olav Dalgard +8 more
TL;DR: A comprehensive literature review is provided that systematically describes the adverse effects of Peg-IFN-α and ribavirin on various organ systems and recommends consensus approaches to managing those effects.
Journal ArticleDOI
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age
Scott A. Halperin,Brian J. Ward,Curtis Cooper,Gerald Predy,Francisco Diaz-Mitoma,Marc Dionne,Joanne Embree,Allison McGeer,Paul Zickler,Karl Heinz Moltz,René Martz,Ingo Meyer,Shelly A. McNeil,Joanne M. Langley,Eduardo B. Martins,William L. Heyward,J. Tyler Martin +16 more
TL;DR: A short, two- dose regimen of HBV-ISS induced a superior antibody response than a three-dose regimen of a licensed hepatitis B vaccine and was well tolerated.
Journal ArticleDOI
Cohort Profile: The Canadian HIV–Hepatitis C Co-infection Cohort Study
Marina B. Klein,Sahar Saeed,Hong Yang,Jeffrey I. Cohen,Brian Conway,Curtis Cooper,Pierre Côté,Joseph Cox,John Gill,David Haase,Shariq Haider,Julio S. G. Montaner,Neora Pick,Anita Rachlis,Danielle Rouleau,Roger Sandre,Mark W. Tyndall,Sharon Walmsley +17 more
TL;DR: The growing burden of chronic HCV infection is expected to result in dramatic increases in the rates of cirrhosis, liver failure, hepatocellular carcinoma, transplant needs and related annual healthcare costs in Canada and worldwide.